Picture [iito] No Tracking 650x80px
Document › Details

Optimapharm d.d.. (2/6/19). "Press Release: Optimapharm Acquires Swiss Denothex and Becomes a Leading European Mid-size Clinical Research Organization".

Region Region Switzerland
Organisations Organisation Optimapharm d.d.
  Group Optimapharm (Group)
  Organisation 2 Denothex Ltd. (CH)
  Group Optimapharm (Group)
Products Product clinical research services
  Product 2 oncology
Index terms Index term Denothex–Optimapharm: investment, 201902 acquisition of Denothex Ltd by Optimapharm
  Index term 2 MKS Research–Optimapharm: investment, 2017 acquisition of MKS Research (CZ) by Optimapharm
Person Person Greguric Cicak, Gordana (Otpimapharm 202007– COO before CEO + Founder since 2006)

With the new acquisition Optimapharm expands its presence into core European markets by strengthening service offerings to biotech and medical device companies

Optimapharm, a leading independent clinical research organization (CRO) in Europe, acquired Denothex Ltd., significantly strengthening its presence in key European markets particularly in France, Germany, Switzerland, Spain and Italy and thus broadening its customer base.

Denothex is a boutique CRO headquartered in Switzerland, managing clinical trials of all phases across Europe and Israel, with particular focus on biotechnology and medical devices in oncology.

By consolidating Denothex, Optimapharm is becoming one of the leading mid-size CRO companies in Europe. Optimapharm was established in Zagreb, Croatia, and operates through offices in 14 European countries. It covers markets with a total population of over 500 million people and has the expertise to conduct phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.

“The clinical research market is experiencing a continued rise, and our goals grow with it. With the combination of continuous organic growth and targeted investments into complementary organizations, we have very successfully established ourselves as one of the leading players in the field of clinical research in Europe. We have a proven track record and continue to identify market opportunities and realize acquisitions with a successful integration in order to create more value for our clients, employees and shareholders. “We are enthusiastic about the acquisition of Denothex, which further strengthens our oncology and medical device expertise” said Gordana Greguric Cicak, CEO of Optimapharm.

In late 2017 Optimapharm successfully acquired and consolidated the Czech company MKS Research, and in November of 2018 attracted a EUR 10 million investment by the Accession Mezzanine Capital fund.

“We have become part of an ambitious fast-growing company with well-structured study operations support and services. The integration with Optimapharm provides our customers with broader access to clinical study centers and patients. We very much look forward to becoming part of such a prosperous organization“, said Dr. Marc Salzberg, Chairman of Denothex.

Since it was founded, Optimapharm has conducted more than 280 clinical studies in 20 countries across Europe and Israel. Demand for CRO services continues to grow steadily, and substantially exceeds the growth rates of the economy globally. According to the 2017 New Market Research Report, the value of the global market for conducting clinical research by 2021 will reach nearly USD 50 billion. The largest market is the US, which accounts for 40 percent, whilst Europe remains the second largest market.

Record changed: 2020-08-06


Picture [iito] Plain Stupid Simple 650x80px

More documents for Optimapharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top